Evaluation of F-18 Tetrafluoroborate PETCT Compared to F-18 FDG PETCT for Detecting Lesions in Differentiated Thyroid Cancer After Surgery and Radioactive Iodine Therapy

What this Trial Is About

Researchers are evaluating imaging techniques for patients with differentiated thyroid cancer who have undergone surgery and radioactive iodine therapy but show elevated serum thyroglobulin Tg andor anti-thyroglobulin ATg levels during follow-up. The study compares a new imaging agent, F-18 Tetrafluoroborate TFB PETCT, with the standard F-18 Fluorodeoxyglucose FDG PETCT in detecting cancer lesions. F-18 TFB targets thyroid cancer cells through a mechanism similar to I-131 but has shown higher specificity in earlier studies. Participants receive F-18 TFB whole-body PETCT scans as the investigational imaging method. This diagnostic test is assessed for its ability to detect lesions compared to standard methods. The study does not involve treatment drugs but focuses on imaging accuracy and diagnostic performance in this patient group. During the study, researchers will measure how well F-18 TFB PETCT identifies cancer lesions and analyze its positivity rate. They will also study how imaging measurements relate to serum Tg and ATg levels. The main outcome is diagnostic accuracy measured over nine months after the first patient enrollment, with safety and performance monitored throughout the study.

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer